MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

219.7 -1.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

218.86

Massimo

221.85

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-3.14% downside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2B

11B

Apertura precedente

221.18

Chiusura precedente

219.7

Notizie sul Sentiment di mercato

By Acuity

17%

83%

14 / 361 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 gen 2026, 23:29 UTC

Azioni calde

Stocks to Watch: Atossa Therapeutics, Union Pacific

17 gen 2026, 15:06 UTC

Acquisizioni, Fusioni, Takeovers

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 gen 2026, 03:10 UTC

Acquisizioni, Fusioni, Takeovers

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 gen 2026, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 gen 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 gen 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Auto & Transport Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 gen 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

16 gen 2026, 21:48 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 gen 2026, 21:41 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 gen 2026, 21:38 UTC

Acquisizioni, Fusioni, Takeovers

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 gen 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 gen 2026, 20:44 UTC

Utili

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 gen 2026, 20:42 UTC

Discorsi di Mercato

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 gen 2026, 20:28 UTC

Discorsi di Mercato

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 gen 2026, 19:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 gen 2026, 18:53 UTC

Discorsi di Mercato

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 gen 2026, 18:41 UTC

Discorsi di Mercato

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 gen 2026, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

16 gen 2026, 17:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

16 gen 2026, 17:03 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

16 gen 2026, 17:03 UTC

Discorsi di Mercato

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

-3.14% in calo

Previsioni per 12 mesi

Media 212.8 USD  -3.14%

Alto 265 USD

Basso 170 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

14 / 361 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat